Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

CAMBRIDGE, Mass., July 06, 2007 /PRNewswire-FirstCall/ -- Genzyme Corp. announced top-line data today from the first of two Phase 3 clinical studies to assess the safety and efficacy of tolevamer liquid, an investigational, non-antibiotic, polymer therapy for patients with Clostridium difficile associated diarrhea (CDAD). The second Phase 3 study of tolevamer liquid is fully enrolled and results are expected later this year.

In this first Phase 3 study known as the Polymer Alternative for CDAD Treatment (PACT) study, tolevamer liquid did not meet its primary endpoint of non-inferiority to the standard prescribed oral dose of the antibiotic vancomycin, as measured by the percent of patients with resolution of CDAD. This result contrasts with the findings from Genzyme's earlier Phase 2 study of a solid oral dosage formulation of tolevamer that met its primary endpoint of non-inferiority compared to vancomycin.

Consistent with recent published studies, high rates of CDAD recurrences were observed in patients treated with either vancomycin or metronidazole. High CDAD recurrence rates were not observed in patients treated with tolevamer liquid. Tolevamer liquid was generally well tolerated with no unanticipated safety concerns. Data from this first Phase 3 study is expected to be presented at a future medical conference.

"These are disappointing results that alter our expectations about the potential for commercializing tolevamer in the near future," stated Henri A. Termeer, chairman and chief executive officer of Genzyme Corp. "The results of our second Phase 3 study will be available later this year and will help us determine what contribution tolevamer might be able to make in addressing this serious unmet medical need."

C. difficile has become one of the most significant infection control concerns in healthcare today. Physicians worldwide are confronting a worsening epidemic, with an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/6/2009)... Nov. 6 DUSA Pharmaceuti...y company that is developing and marketing Levulan...ucts focused on patients with common skin conditio...Executive Officer, will present a corporate overvi...9 on Tuesday, November 10, 2009 at 10:00 a.m. ET a...
(Date:11/6/2009)...v. 6 Repossessions and liquidation...hird quarter of 2009 declined as compared to simil...nagement,s NasTrac Quarterly Index (NQI). The fig...or both repossessions and orderly liquidations, al...truction and printing equipment, offering mixed ne...
(Date:11/6/2009)... America,s Specialty Me...p of mid-market and smaller innovator pharmaceutic...3962, the "Affordable Health Care for America Act,...ese smaller companies fear that the cumulative eff...er their efforts to bring new medicines to market....
Breaking Medicine Technology:NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2Study questions need for routine intervention in patients with renovascular disease 59418 1Study questions need for routine intervention in patients with renovascular disease 59418 2Study questions need for routine intervention in patients with renovascular disease 59418 3Small smaller smallest 3F ASU researchers create molecular diode 14460 1Small smaller smallest 3F ASU researchers create molecular diode 14460 2Small smaller smallest 3F ASU researchers create molecular diode 14460 3AHIP Is Right and May Be Low 59417 1AHIP Is Right and May Be Low 59417 2AHIP Is Right and May Be Low 59417 3
...ing international experts on the,asbestos-related ...egivers,loved ones and advocates to share the late...he Mesothelioma Applied Research Foundation,s,Inte...8, Thursday, June 26,- Saturday, June 28 at the Hy...The Symposium, organized annually by the Meso Foun...
...ey role in discovery, ITASCA, Ill. and SYDNEY, Au...atients, conducted by the Universities of,Cambridg...dical Holdings,Limited,s SphygmoCor(R) has found t... having "high normal" systolic blood pressure thro...y be at serious,cardiovascular risk. This is becau...
Other Medicine Technology:International Symposium on Malignant Mesothelioma 2008 2New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk 2New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk 3
(Date:11/7/2009)...HOUSTON, Nov. 7, The Am... 2009 Benjamin Rush Award for Citizenship and Comm...ologist from Chicago, IL. The award recognizes phy...ssional call of duty to make an outstanding public.... Kraff received the award today during the openin...
(Date:11/7/2009)...HOUSTON, Nov. 7 Calling this a "de...n (AMA), the AMA President J. James Rohack, M.D., ...ians from all state and medical specialty societie...aking meeting, where health system reform will top.../cgi-bin/prnh/20081209/AMALOGO ) ,, "Over the...
(Date:11/7/2009)... Brown: "Faithful Catholics have a responsibility...negotiate the status quo." ,, WASHINGTON, Nov...ague president Judie Brown released the following ...will support Speaker Nancy Pelosi,s Affordable Hea...amendment preserving the status quo for abortion i...
(Date:11/7/2009)...GTON, Nov. 7 Americans United for Life Action end...tupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-S...al money from going to abortion in health care ref...nt and CEO Dr. Charmaine Yoest said, "Americans Un...Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith A...
(Date:11/7/2009)... fight back to stem a growing problem across the U...-- Nearly half of students at four-year colleges d... binge drinking -- downing five or more alcoholic ...entifying alcohol as a drug," said Jenny Hwang, as...eling center at Stony Brook University on Long Isl...
Breaking Medicine News(10 mins):Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:Americans United for Life Action Endorses a Vote for the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment and Sends Score Letter to House Members 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3
...eleased today by SEIU UHW: , , NOTE TO EDITORS: ... budget is expected to reach Congress--several hun...area will rally to support the president,s vision ...eleased a new report today explaining the impact o...
...ies(TM), a division of Ben Venue Laboratories, Inc...nate Injection. This product is AP rated and is e...riptan is a vascular headache suppressant indicate...njection is not for use in the management of hemip...
...s say, , , WEDNESDAY, Feb. 25 (HealthDay N...ociated with cystic fibrosis. , Dr. Christopher Ka...Center, and an international team of colleagues de...ies of white blood cells called neutrophils. , Cru...
...d medical device developed by University at Buffal...settings the powerful and effective method of anes...ting room., The new UB ventilator has the potenti...sed in the ICU. It also is expected to be more cos...
...t guideline produced by the American Society of Cl... Association (AUA) recommends that healthy men who...ow no symptoms of the disease should talk to their...ich can contribute to the growth of prostate cance...
...rancisco, and East Bay children and teens, ages 6 ...loved one, or friend are invited to apply for Hosp...kend, Camp Erin™ Oakland/Bay Area, which wil... teens, ages 6 to 17, who are coping with the deat...
Other Medicine News:Health News:L.A. Area SEIU Members Gear Up to Support Effort to Fix Healthcare; Plan Rally for Thursday 2Health News:Bedford Laboratories(TM) to Begin Shipping Sumatriptan Succinate Injection 2Health News:Study Pinpoints New Gene for Cystic Fibrosis 2Health News:Study Pinpoints New Gene for Cystic Fibrosis 3Health News:UB-designed ventilator can safely sedate ICU patients for less 2Health News:UB-designed ventilator can safely sedate ICU patients for less 3Health News:New ASCO/AUA guideline recommends men and their doctors discuss using 5-ARIs to reduce prostate cancer risk 2Health News:Apply for Free, Youth Grief Support Camp Hosted by Hospice By The Bay in August 2Health News:Apply for Free, Youth Grief Support Camp Hosted by Hospice By The Bay in August 3
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: